ANALYSIS OF INDUSTRIAL PRACTICE OF DRUG QUALITY RISK MANAGEMENT IN RUSSIAN PHARMACEUTICAL ENTERPRISES

The aim of the research was to study the current industrial practice of drug quality risk management in Russian pharmaceutical enterprises, including the assessment of the main problems during the implementation of the risk management system and its compliance with the accepted international approaches.

Materials and methods. In the period from 6 April to 10 May 2020, an online survey of the leading employees in the field of quality assurance of Russian manufacturers was conducted. In the survey, the questionnaire was based on the results of the authors’ analysis of the national regulatory legal acts of the Russian Federation, the European Union countries, international guidelines of the EAEU, ICH and WHO in this area. 111 people took part in the survey, the return of questionnaires was 11.5%.

Results. The data obtained indicate the prevalence of a superficial approach to quality risk management in the Russian pharmaceutical industry, the presence of objective and subjective reasons that hinder the effective implementation of these methods, the fragmentation of the systems used and, in most cases, their ineffective use. The respondents believe that the most significant reasons for the difficulties in implementing this methodology, are the lack of recommendations from the Ministry of Industry and Trade of Russia on creating an effective quality risk management system and a shortage of the specialists who are ready to work in the area of this industry. The survey revealed rather large gaps in the deployment of a risk management system at the enterprise and separation from the established international practice.

Conclusions. The data obtained indicate the extreme urgency of developing recommendations for a quality risk management system, which should be based upon and supported by Russian regulatory legal acts and international experience in this area. The authors propose highlights for these recommendations.

1. Ivashina MM, Natsypaeva EA, Popova LF. The risk-based approach as the direction of the improvement of the quality management system of industrial enterprises. Economic Journal. 2018;2 (50):28–38. Russian

2. Chernenkii AV. Application of risk-oriented approach for creation of quality management system. International research journal. 2016;8(50) Part 1: 92–96. Russian.

3. Claycamp H Gregg. Probability Concepts in Quality Risk Management. PDA Journal of Pharmaceutical Science and Technology January. 012;66(1):78–89.

4. O’Donnell K, Greene A., Zwitkovits M, Calnan N. Quality Risk Management: Putting GMP Controls First. PDA Journal of Pharmaceutical Science and Technology. 2012;66(3):243–261.

5. Vega H, Rivera R. Quality Risk Management for Legacy Products in CMOs. Pharmaceutical Engineering. 2016: 84–90.

6. Assem A. Implementation of Quality Risk Management for Manufacturing of a Non-Sterile Pharmaceutical Product – Case study. Cohesive Journal of Microbiology & Infectious Disease. 2018;1(3).

7. Powar PV, Shirode DS. Quality by Design: Predefined Objected Quality and Quality Risk Management. Int. J. Pharm. Sci. Rev. Res. 2020;65(1):14–26.

8. Reddy VV, Vishal Gupta N, Raghunandan HV, Nitin Kashyap U. Quality Risk Management in Pharmaceutical Industry: A Review. International Journal of Pharm Tech Research. 2014;6(3):908–914.

9. Vartak1 RP, Bhagure GR. Quality Risk Management in Pharmaceutical Industry-A Overview. Asian Journal of Chemistry. 2012;24(12):5576–5578.

10. Vesper J, O’Donnell K. Current Challenges in Implementing Quality Risk Management. Pharmaceutical Engineering. 2016:73–79.

11. Sattar Khan A, Khan F, Rao N. Quality risk management in pharmaceutical industries. International journal of research in pharmacy and chemistry. – 2020;10(2):215–223.

12. Mollah H., Baseman H., Long M. Risk Management Applications in Pharmaceutical and Biopharmaceutical Manufacturing. Wiley. 2013: 414.

13. Alexandrov AV. Vospitanie privychki k upravleniiu riskami dlia kachestva. Pharmaceutical industry. 2015;4(51):112–114. Russian

14. Alexandrov A.V. Faktor subjektivnosti pri ocenke riska po kachestvuy. Pharmaceutical industry. 2011;5(28):116–119. Russian

15. Hajimolaali M, Asl AA. Quality Risk Assessment Production of Beta Lactams by FMEA Model and Fuzzy Theory Method. Gen Med (Los Angel). 2016;4(1).

16. Omar A Ismael, Moyassar I. Ahmed. Using Quality Risk Management in Pharmaceutical Industries: A Case Study. Quality Access to success. 2020;21(178):106–113.

17. Mandhare TA, Khuspe PR, Nangare PS, Vyavhare RD. Quality Risk Management: A Review. American Journal of PharmTech Research. 2018;8(2):56–86.

18. Parashar N, Geete A. Step wise approach for the Quality Risk Management (QRM) in pharmaceutical industries. Available from: https://www.linkedin.com/pulse/stepwise-approach-quality-risk-management-qrm-neha / (accessed: 19.02.2021).

19. Mire-Sluis A, Ramnarine E, Siemiatkoski J et al. Practical Applications of Quality Risk Management. BioProcess International. 2010;8(3):20–32.

20. H. Gregg Claycamp. Perspective on Quality Risk Management of Pharmaceutical Quality. Drug Information Journal. 2007;41:353–367.

21. Alemayehu D, Alvir J, Levenstein M, Nickerson D. A data-driven approach to quality risk management. Perspectives in Clinical Research. 2013;4(4):221–226.

22. O’Connor T, Yang X, Tian G, Chatterjee S, Lee S. Quality risk management for pharmaceutical manufacturing: The role of process modeling and simulations. Predictive Modeling of Pharmaceutical Unit Operations. 2017: 15–37.

23. Das A, Kadwe1 P, Mishra JK, Moorkoth S. Quality Risk Management (QRM) in Pharmaceutical Industry: Tools and Methodology. International Journal of Pharmaceutical Quality Assurance. 2014;5(3):13–21.

24. Germany Trade & Invest. Industry overview. The Pharmaceutical Industry in Germany. Issue 2017/2018. Available from: https://www.vfa.de/embed/the-pharmaceutical-industry-in-germany.pdf (accessed: 30.09.2020).

25. The European Expertise Center for Pharmacy Education and Training (EEC-PET). Pharmine project. Country profiles. Available from: https://eec-pet.eu/pharmacy-education/country-profiles/ (accessed: 30.09.2020).

26. Haddad G., Greene A. Quality Risk Management: A RoleBased Competency Model. PDA Journal of Pharmaceutical Science and Technology. 2020;74(1):58–72.